Corporate Member Eli Lilly - NEW Approval

Corporate Member Eli Lilly - NEW Approval

LARTRUVO (olaratumab)
April, 2018

LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. 

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members